{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:47:24Z","timestamp":1794350844848,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,8,30]],"date-time":"2011-08-30T00:00:00Z","timestamp":1314662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s10552-011-9832-6","type":"journal-article","created":{"date-parts":[[2011,8,29]],"date-time":"2011-08-29T05:15:59Z","timestamp":1314594959000},"page":"1553-1561","source":"Crossref","is-referenced-by-count":26,"title":["Regular aspirin use and breast cancer risk in US Black Women"],"prefix":"10.1007","volume":"22","author":[{"given":"Jaclyn L. F.","family":"Bosco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Boggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E.","family":"Hatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,30]]},"reference":[{"key":"9832_CR1","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q","volume":"82","author":"L Rosenberg","year":"1998","unstructured":"Rosenberg L, Louik C, Shapiro S (1998) Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82:2326\u20132333","journal-title":"Cancer"},{"key":"9832_CR2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/jnci\/83.5.355","volume":"83","author":"L Rosenberg","year":"1991","unstructured":"Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83:355\u2013358","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","volume":"94","author":"MJ Thun","year":"2002","unstructured":"Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252\u2013266","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1592\/phco.22.5.303.33189","volume":"22","author":"CR Meier","year":"2002","unstructured":"Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22:303\u2013309","journal-title":"Pharmacotherapy"},{"key":"9832_CR5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10552-006-0033-7","volume":"17","author":"C Bosetti","year":"2006","unstructured":"Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17:871\u2013888","journal-title":"Cancer Causes Control"},{"key":"9832_CR6","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1001\/jama.291.20.2488","volume":"291","author":"RN DuBois","year":"2004","unstructured":"DuBois RN (2004) Aspirin and breast cancer prevention. JAMA 291:2488\u20132489","journal-title":"JAMA"},{"key":"9832_CR7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/94.8.606","volume":"94","author":"The Endogenous Hormones Breast Cancer Collaborative Group","year":"2002","unstructured":"The Endogenous Hormones Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606\u2013616","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jnci\/90.6.455","volume":"90","author":"D Hwang","year":"1998","unstructured":"Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90:455\u2013460","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR9","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1210\/jc.2004-2029","volume":"90","author":"ES Diaz-Cruz","year":"2005","unstructured":"Diaz-Cruz ES, Shapiro CL, Brueggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90:2563\u20132570","journal-title":"J Clin Endocrinol Metab"},{"key":"9832_CR10","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/jnci\/djn347","volume":"100","author":"LR Howe","year":"2008","unstructured":"Howe LR, Lippman SM (2008) Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst 100:1420\u20131423","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/pmed.1995.1022","volume":"24","author":"RE Harris","year":"1995","unstructured":"Harris RE, Namboodiri KK, Stellman SD, Wynder EL (1995) Breast cancer and NSAID use: heterogeneity of effect in a case\u2013control study. Prev Med 24:119\u2013120","journal-title":"Prev Med"},{"key":"9832_CR12","first-page":"6096","volume":"63","author":"RE Harris","year":"2003","unstructured":"Harris RE, Chlebowski RT, Jackson RD et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women\u2019s Health Initiative. Cancer Res 63:6096\u20136101","journal-title":"Cancer Res"},{"key":"9832_CR13","first-page":"1586","volume":"11","author":"TW Johnson","year":"2002","unstructured":"Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomark Prev 11:1586\u20131591","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"9832_CR14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9665-x","volume":"109","author":"A Ready","year":"2008","unstructured":"Ready A, Velicer C, McTiernan A, White E (2008) NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 109:533\u2013543","journal-title":"Breast Cancer Res Treat"},{"key":"9832_CR15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1055-9965.EPI-05-0472","volume":"14","author":"EJ Jacobs","year":"2005","unstructured":"Jacobs EJ, Thun MJ, Connell CJ et al (2005) Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large US cohort. Cancer Epidemiol Biomark Prev 14:261\u2013264","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"9832_CR16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/jnci\/88.14.988","volume":"88","author":"KM Egan","year":"1996","unstructured":"Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88:988\u2013993","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/archinternmed.2008.537","volume":"169","author":"AH Eliassen","year":"2009","unstructured":"Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE (2009) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses\u2019 Health Study II. Arch Intern Med 169:115\u2013121","journal-title":"Arch Intern Med"},{"key":"9832_CR18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/dji140","volume":"97","author":"SF Marshall","year":"2005","unstructured":"Marshall SF, Bernstein L, Anton-Culver H et al (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97:805\u2013812","journal-title":"J Natl Cancer Inst"},{"key":"9832_CR19","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/aje\/kwm195","volume":"166","author":"JK Gill","year":"2007","unstructured":"Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166:1150\u20131158","journal-title":"Am J Epidemiol"},{"key":"9832_CR20","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/bcr2089","volume":"10","author":"G Gierach","year":"2008","unstructured":"Gierach G, Lacey J, Schatzkin A et al (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10:R38","journal-title":"Breast Cancer Res"},{"key":"9832_CR21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.294.1.47","volume":"294","author":"NR Cook","year":"2005","unstructured":"Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women\u2019s Health Study: a randomized controlled trial. JAMA 294:47\u201355","journal-title":"JAMA"},{"key":"9832_CR22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bjc.6604240","volume":"98","author":"SM Zhang","year":"2008","unstructured":"Zhang SM, Cook NR, Manson JE, Lee I-M, Buring JE (2008) Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98:989\u2013991","journal-title":"Br J Cancer"},{"key":"9832_CR23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1023\/B:CACO.0000007973.59863.66","volume":"14","author":"P Moorman","year":"2003","unstructured":"Moorman P, Grubber J, Millikan R, Newman B (2003) Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 14:915\u2013922","journal-title":"Cancer Causes Control"},{"key":"9832_CR24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/A:1011284719186","volume":"12","author":"JR Palmer","year":"2001","unstructured":"Palmer JR, Rao SR, Adams-Campbell LL, Rosenberg L (2001) Height and breast cancer risk: results from the Black Women\u2019s Health Study (United States). Cancer Causes Control 12:343\u2013348","journal-title":"Cancer Causes Control"},{"issue":"S1","key":"9832_CR25","first-page":"S168","volume":"12","author":"KE Kelley","year":"2003","unstructured":"Kelley KE, Kelley TP, Kaufman DW, Mitchell AA (2003) The Slone Drug Dictionary: a research driven pharmacoepidemiology tool. Pharmacoepidemiol Drug Saf 12(S1):S168\u2013S198","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"9832_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1207\/S15327914NC4501_1","volume":"45","author":"GD Stephenson","year":"2003","unstructured":"Stephenson GD, Rose DP (2003) Breast cancer and obesity: an update. Nutr Cancer 45:1\u201316","journal-title":"Nutr Cancer"},{"key":"9832_CR27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/01.ede.0000251167.75581.98","volume":"18","author":"EM Monninkhof","year":"2007","unstructured":"Monninkhof EM, Elias SG, Vlems FA et al (2007) Physical activity and breast cancer: a systematic review. Epidemiol 18:137\u2013157","journal-title":"Epidemiol"},{"key":"9832_CR28","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0140-6736(02)11140-8","volume":"360","author":"PR Band","year":"2002","unstructured":"Band PR, Le ND, Fang R, Deschamps M (2002) Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet 360:1044\u20131049","journal-title":"Lancet"},{"key":"9832_CR29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(06)70577-0","volume":"7","author":"P Boffetta","year":"2006","unstructured":"Boffetta P, Hashibe M (2006) Alcohol and cancer. Lancet Oncol 7:149\u2013156","journal-title":"Lancet Oncol"},{"key":"9832_CR30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/oxfordjournals.epirev.a036112","volume":"15","author":"JL Kelsey","year":"1993","unstructured":"Kelsey JL (1993) Breast cancer epidemiology: summary and future directions. Epidemiol Rev 15:256\u2013263","journal-title":"Epidemiol Rev"},{"key":"9832_CR31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/oxfordjournals.epirev.a036115","volume":"15","author":"JL Kelsey","year":"1993","unstructured":"Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. Epidemiol Rev 15:36\u201347","journal-title":"Epidemiol Rev"},{"key":"9832_CR32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/oxfordjournals.epirev.a036118","volume":"15","author":"JL Kelsey","year":"1993","unstructured":"Kelsey JL, Horn-Ross PL (1993) Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 15:7\u201316","journal-title":"Epidemiol Rev"},{"key":"9832_CR33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34:187\u2013220","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"9832_CR34","doi-asserted-by":"crossref","unstructured":"Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"9832_CR35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1006\/pmed.1999.0518","volume":"29","author":"PF Coogan","year":"1999","unstructured":"Coogan PF, Rao SR, Rosenberg L et al (1999) The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 29:72\u201376","journal-title":"Prev Med"},{"key":"9832_CR36","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s10552-010-9579-5","volume":"21","author":"TM Brasky","year":"2010","unstructured":"Brasky TM, Bonner MR, Moysich KB et al (2010) Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 21:1503\u20131512","journal-title":"Cancer Causes Control"},{"key":"9832_CR37","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/humrep\/deg435","volume":"18","author":"ATn Pedersen","year":"2003","unstructured":"Pedersen ATn, Ottesen B (2003) Issues to debate on the Women\u2019s Health Initiative (WHI) study. Epidemiology or randomized clinical trial\u2014time out for hormone replacement therapy studies? Hum Reprod 18:2241\u20132244","journal-title":"Hum Reprod"},{"key":"9832_CR38","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/sj.bjc.6602003","volume":"91","author":"LA Garcia Rodriguez","year":"2004","unstructured":"Garcia Rodriguez LA, Gonzalez-Perez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 91:525\u2013529","journal-title":"Br J Cancer"},{"key":"9832_CR39","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/bcr2482","volume":"12","author":"D Cronin-Fenton","year":"2010","unstructured":"Cronin-Fenton D, Pedersen L, Lash T, Friis S, Baron J, S\u00f8rensen HT (2010) Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case\u2013control study. Breast Cancer Res 12:R15","journal-title":"Breast Cancer Res"},{"key":"9832_CR40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2407-6-27","volume":"6","author":"R Harris","year":"2006","unstructured":"Harris R, Beebe-Donk J, Alshafie G (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27","journal-title":"BMC Cancer"},{"key":"9832_CR41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1471-2407-5-159","volume":"5","author":"E Rahme","year":"2005","unstructured":"Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M (2005) Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 5:159","journal-title":"BMC Cancer"},{"key":"9832_CR42","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1001\/jama.291.20.2433","volume":"291","author":"MB Terry","year":"2004","unstructured":"Terry MB, Gammon MD, Zhang FF et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433\u20132440","journal-title":"JAMA"},{"key":"9832_CR43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ijc.22656","volume":"121","author":"L Gallicchio","year":"2007","unstructured":"Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ (2007) Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121:211\u2013215","journal-title":"Int J Cancer"},{"key":"9832_CR44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CEJ.0b013e3282b6fd55","volume":"17","author":"S Friis","year":"2008","unstructured":"Friis S, Thomassen L, S\u00f8rensen HT et al (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Euro J Cancer Prev 17:88\u201396","journal-title":"Euro J Cancer Prev"},{"key":"9832_CR45","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1158\/1055-9965.EPI-09-0975","volume":"19","author":"MA Gates","year":"2010","unstructured":"Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE (2010) Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomark Prev 19:1033\u20131041","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"9832_CR46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00045391-200501000-00008","volume":"12","author":"GG Graham","year":"2005","unstructured":"Graham GG, Scott KF (2005) Mechanism of action of paracetamol. Am J Therap 12:46\u201355","journal-title":"Am J Therap"},{"key":"9832_CR47","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1460-9592.2008.02764.x","volume":"18","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ (2008) Paracetamol (acetaminophen): mechanisms of action. Paediatr Anaesth 18:915\u2013921","journal-title":"Paediatr Anaesth"},{"key":"9832_CR48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clpt.2005.09.009","volume":"79","author":"DM Aronoff","year":"2006","unstructured":"Aronoff DM, Oates JA, Boutaud O (2006) New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Therapeutics 79:9\u201319","journal-title":"Clin Pharmacol Therapeutics"},{"key":"9832_CR49","first-page":"1322","volume":"53","author":"MJ Thun","year":"1993","unstructured":"Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53:1322\u20131327","journal-title":"Cancer Res"},{"key":"9832_CR50","first-page":"525","volume":"91","author":"LA Garcia Rodriguez","year":"2004","unstructured":"Garcia Rodriguez LA, Gonzalez-Perez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 91:525\u2013529","journal-title":"Cancer Causes Control"},{"key":"9832_CR51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00001648-199403000-00002","volume":"5","author":"DM Schreinemachers","year":"1994","unstructured":"Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiol 5:135\u2013146","journal-title":"Epidemiol"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-011-9832-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-011-9832-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-011-9832-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T10:56:54Z","timestamp":1741517814000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-011-9832-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,30]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["9832"],"URL":"https:\/\/doi.org\/10.1007\/s10552-011-9832-6","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,30]]}}}